JP2014517750A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014517750A5 JP2014517750A5 JP2014510302A JP2014510302A JP2014517750A5 JP 2014517750 A5 JP2014517750 A5 JP 2014517750A5 JP 2014510302 A JP2014510302 A JP 2014510302A JP 2014510302 A JP2014510302 A JP 2014510302A JP 2014517750 A5 JP2014517750 A5 JP 2014517750A5
- Authority
- JP
- Japan
- Prior art keywords
- supar
- support
- cartridge
- housing
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 21
- 210000004369 blood Anatomy 0.000 claims description 16
- 239000008280 blood Substances 0.000 claims description 16
- 102000004506 Blood Proteins Human genes 0.000 claims description 15
- 108010017384 Blood Proteins Proteins 0.000 claims description 15
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 13
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 13
- 239000012530 fluid Substances 0.000 claims description 13
- 102000005962 receptors Human genes 0.000 claims description 13
- 108020003175 receptors Proteins 0.000 claims description 13
- 229960005356 urokinase Drugs 0.000 claims description 13
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 claims description 10
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 claims description 10
- 102000008607 Integrin beta3 Human genes 0.000 claims description 4
- 108010020950 Integrin beta3 Proteins 0.000 claims description 4
- 230000027455 binding Effects 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 239000003547 immunosorbent Substances 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 210000000557 podocyte Anatomy 0.000 claims description 4
- 238000004440 column chromatography Methods 0.000 claims description 3
- 238000005374 membrane filtration Methods 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 239000012503 blood component Substances 0.000 claims description 2
- 239000000835 fiber Substances 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 230000009870 specific binding Effects 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 6
- 210000001772 blood platelet Anatomy 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161457665P | 2011-05-09 | 2011-05-09 | |
| US61/457,665 | 2011-05-09 | ||
| PCT/US2012/000240 WO2012154218A2 (en) | 2011-05-09 | 2012-05-09 | Reducing soluble urokinase receptor in the circulation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014517750A JP2014517750A (ja) | 2014-07-24 |
| JP2014517750A5 true JP2014517750A5 (cg-RX-API-DMAC7.html) | 2015-06-11 |
| JP6055464B2 JP6055464B2 (ja) | 2016-12-27 |
Family
ID=47139854
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014510302A Active JP6055464B2 (ja) | 2011-05-09 | 2012-05-09 | 循環血中の可溶性ウロキナーゼ受容体の低減 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9867923B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2707055B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6055464B2 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2765006T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012154218A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2608804A4 (en) * | 2010-08-27 | 2015-03-11 | Univ Miami | TREATMENT OF KIDNEY DISEASES |
| WO2012154218A2 (en) | 2011-05-09 | 2012-11-15 | The University Of Miami | Reducing soluble urokinase receptor in the circulation |
| JP6438474B2 (ja) * | 2013-08-01 | 2018-12-12 | ザ ジェネラル ホスピタル コーポレイション | 非グリコシル化suPARバイオマーカー及びその使用 |
| CN103933615B (zh) * | 2014-04-08 | 2015-10-28 | 华南理工大学 | 一种用于肾小球滤过膜修复的自组装多孔聚合物膜及其制备方法与应用 |
| WO2017040488A1 (en) * | 2015-08-31 | 2017-03-09 | Rush University Medical Center | Prediction of kidney disease, severity and related treatment approaches |
| WO2017053976A1 (en) * | 2015-09-25 | 2017-03-30 | The General Hospital Corporation | DIAGNOSTIC ASSAYS FOR SUPAR-β3 INTEGRIN DRIVEN KIDNEY DISEASES |
| EP3735281B1 (en) | 2018-01-05 | 2024-11-27 | Path Ex, Inc. | Device for the capture and removal of disease material from fluids |
| JP2022513317A (ja) * | 2018-09-28 | 2022-02-07 | ヨッヘン ライザー | suPARならびに急性腎傷害の予測および治療 |
| US20230348613A1 (en) * | 2020-06-05 | 2023-11-02 | The Regents Of The University Of California | Methods and antibodies in treatment of focal segmental glomerulosclerosis (fsgs) |
| WO2022125776A2 (en) | 2020-12-09 | 2022-06-16 | Siwa Corporation | Methods and compositions for treating kidney diseases |
| JP7553105B2 (ja) * | 2021-03-04 | 2024-09-18 | 学校法人産業医科大学 | 巣状分節性糸球体硬化症の発症時期を推定する方法 |
| TWI830166B (zh) | 2022-03-08 | 2024-01-21 | 國立成功大學 | 病理切片影像的脂滴分割方法與電腦程式產品 |
| JP2024034246A (ja) * | 2022-08-31 | 2024-03-13 | 国立大学法人群馬大学 | 特発性ネフローゼ症候群の検査方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5942492A (en) | 1996-11-12 | 1999-08-24 | Angstrom Pharmaceuticals, Inc. | Cyclic peptides that bind to urokinase-type plasminogen activator receptor |
| US6794358B1 (en) | 1997-03-28 | 2004-09-21 | Brigham And Women's Hospital | Peptide ligands of the urokinase receptor |
| US6774102B1 (en) | 1999-09-29 | 2004-08-10 | Gambro Dialysatoren Gmbh & Co. Kg | Extracorporeal endotoxin removal method |
| SE0201257D0 (sv) * | 2002-04-25 | 2002-04-25 | Medical Invest In Sweden Ab | Improved Separation |
| US7138230B2 (en) | 2002-12-06 | 2006-11-21 | Renovar, Inc. | Systems and methods for characterizing kidney diseases |
| US7560244B2 (en) | 2003-06-04 | 2009-07-14 | Joslin Diabetes Center, Inc. | Method of evaluating a subject for risk or predisposition of reduced renal function over time |
| AU2005240082B2 (en) * | 2004-04-30 | 2009-07-23 | Innatus Corporation | Method and system to remove soluble TNFR1,TNFR2, and IL2 in patients |
| PL1765397T3 (pl) | 2004-05-25 | 2013-04-30 | Tactic Pharma Llc | Hamujące przeciwciała wiążące kompleks aktywatora plazminogenu typu urokinazy (uPA) i jego receptora (uPAR) |
| WO2007056435A2 (en) | 2005-11-08 | 2007-05-18 | The General Hospital Corporation | Dynamin mediated diseases and associated methods and products |
| US20070244046A1 (en) | 2006-03-29 | 2007-10-18 | Margarita Gutova | Identification and characterization of cancer stem cells and methods of use |
| TW200813091A (en) | 2006-04-10 | 2008-03-16 | Amgen Fremont Inc | Targeted binding agents directed to uPAR and uses thereof |
| US8815519B2 (en) | 2006-12-22 | 2014-08-26 | Hvidovre Hospital | Method for predicting cancer and other diseases |
| JP2011503531A (ja) | 2007-10-26 | 2011-01-27 | ジェネンテック, インコーポレイテッド | ウロキナーゼ型プラスミノーゲン活性化因子(uPA)活性の阻害 |
| EP2730282A1 (en) | 2007-11-08 | 2014-05-14 | The General Hospital Corporation | Methods and compositions for the treatment of proteinuric diseases |
| US20110212083A1 (en) | 2008-11-06 | 2011-09-01 | University Of Miami Office Of Technology Transfer | Role of soluble upar in the pathogenesis of proteinuric kidney disease |
| WO2012154218A2 (en) | 2011-05-09 | 2012-11-15 | The University Of Miami | Reducing soluble urokinase receptor in the circulation |
-
2012
- 2012-05-09 WO PCT/US2012/000240 patent/WO2012154218A2/en not_active Ceased
- 2012-05-09 ES ES12782210T patent/ES2765006T3/es active Active
- 2012-05-09 JP JP2014510302A patent/JP6055464B2/ja active Active
- 2012-05-09 EP EP12782210.4A patent/EP2707055B1/en active Active
- 2012-05-09 US US14/116,470 patent/US9867923B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Koch et al. | Lectin affinity plasmapheresis for middle east respiratory syndrome-coronavirus and Marburg virus glycoprotein elimination | |
| Silliman et al. | Experimental prestorage filtration removes antibodies and decreases lipids in RBC supernatants mitigating TRALI in vivo | |
| Sanchez et al. | The selective therapeutic apheresis procedures | |
| Aucella et al. | Adsorption dialysis: from physical principles to clinical applications | |
| CN102549439B (zh) | 用于吸附铁调素的吸附剂 | |
| JP2014500735A5 (cg-RX-API-DMAC7.html) | ||
| US4512763A (en) | Method and apparatus for selective removal of constituents of blood | |
| CN104725506A (zh) | 一种应用免疫亲和柱纯化人血清前白蛋白多克隆抗体的方法 | |
| US20180093032A1 (en) | Targeted apheresis using binding agents or ligands immobilized on membranes | |
| KR102572488B1 (ko) | 활성화 백혈구-활성화 혈소판 복합체의 제거 재료 | |
| KR20200051578A (ko) | 면역 억제성 백혈구 흡착 재료 및 흡착 칼럼 | |
| Gong et al. | More selective removal of myeloperoxidase‐anti‐neutrophil cytoplasmic antibody from the circulation of patients with vasculitides using a novel double‐filtration plasmapheresis therapy | |
| Lysaght et al. | Closed-loop plasmapheresis | |
| Tonev et al. | Therapeutic plasma exchange in certain immune-mediated neurological disorders: focus on a novel nanomembrane-based technology | |
| Milly et al. | Selenium in renal failure patients | |
| JP2013504751A5 (cg-RX-API-DMAC7.html) | ||
| CN103611504A (zh) | 一种用于血液灌流去除类风湿因子的吸附材料及其制备方法 | |
| Aljadi et al. | Activation of basophils is a new and sensitive marker of biocompatibility in hemodialysis | |
| JP6621414B2 (ja) | 濾過装置 | |
| Tariket et al. | Modeling the effect of platelet concentrate supernatants on endothelial cells: focus on endocan/ESM‐1 | |
| Sakai | Polymethylmethacrylate membrane with a series of serendipity | |
| Effect of different dialysis methods on cellular immunity function of maintenance haemodialysis patients | ||
| JP2010530360A (ja) | 全身性エリテマトーデスを治療するペプチドおよび全身性エリテマトーデスの治療方法 | |
| CN103833843A (zh) | 一种从正常人血浆中提取纯化前白蛋白pa的方法 | |
| JP5250288B2 (ja) | 体液浄化システムの作動方法 |